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Introduction
Conventional teaching asserts that breast neoplasms gen-
erally grow at a given rate and very few if  any regress with-
out treatment.  The fact that large randomized controlled 
trials have demonstrated a significant survival benefit in 
screened groups versus non-screened groups suggests that a 
large number of  invasive breast cancers follow the model of 
progressive tumor growth.  These growing cancers, when 
diagnosed at an earlier stage with mammographic screen-
ing, are amenable to early intervention which reduces mor-
tality.  	
On the other hand, several sources of  evidence suggest 
that the natural history of  some breast cancers may not be 
as straightforward as generally assumed.(1, 2) Mathematical 
models have shown that the number of  cancers detected by 
screening mammography is larger than would be expected 
based on statistics prior to the adoption of  population 
based screening.  Simulations based on these models sug-
gest that some of  these cancers would not have become 
clinically significant.(Fryback DG et al., The case for lim-
ited malignant potential breast cancer, presented at the 
26th Annual Meeting of  the Society for Medical Decision 
Making, 2004)  Studies of  European breast cancer screen-
ing programs (offering mammography to women aged 50-
65) demonstrate an approximately 50% higher cancer de-
tection rate than background (non-screened) rates in the 
same age groups.(3, 4) In Norway’s breast cancer screening 
program, the cumulative incidence of  breast cancer is sta-
tistically significantly greater than the prevalence round.  
Some investigators theorize that a proportion of  these inci-
dent cases might never have become clinically manifest 
without screening. (Zahl PH et al, Frontiers in Cancer Pre-
vention Research, presented at Third Annual American 
Association for Cancer Research (AACR) International 
Conference, 2004) 
Furthermore, if  all of  these cancers were not detected 
but were left to progress, the rate of  breast cancers in older 
women (>65) in non-screened populations would be triple 
what is actually seen.(3,4) Therefore, to account for these 
discrepancies, scientists have asserted the likelihood that 
some subclinical breast cancers may not progress or may 
regress spontaneously.(5)  The purpose of  this report is to 
describe a case of  apparent breast cancer regression and 
recrudescence associated with hormone replacement ther-
apy (HRT). 
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Case Report
Our institutional review board granted us an exemption 
from their review for this report.  A 64-year-old post-
menopausal female with a four year history of  hormone 
replacement therapy (Estradiol, 1 mg po, q.d. and Methyl-
progesterone, 2.5 mg po q.d.) underwent screening mam-
mography in December of  2001.  This examination re-
vealed a mass in the inner left breast (Figure 1a and b).  
Diagnostic views confirmed this finding (Figure 1c) and 
an MRI was recommended for further evaluation.  A dy-
namic contrast-enhanced MRI examination in February 
2002 revealed a suspicious 9 mm mass in the upper inner 
left breast (Figure 2 a-d) corresponding to the mammog-
raphic finding and demonstrating rapid uptake of  gadolin-
ium with washout in the delayed phase.  Ultrasound was 
not performed at this time.  Needle localization by MRI 
was recommended because the interpreting radiologist 
thought the abnormality could be more confidently identi-
fied on this modality.  The patient discontinued HRT at this  
time.  
Eight weeks later the patient returned for MRI-guided 
needle localization.  Repeat MRI examination with light 
breast compression but an otherwise identical imaging pro-
tocol showed that the MRI abnormality had decreased in 
size to 4 mm (Figure 3 a-d) and the enhancement was less 
marked.  At this time, the MRI localization procedure was 
canceled.  The case was presented at our monthly breast 
imaging conference.  The mammographic abnormality was 
thought to be suspicious enough to warrant biopsy despite 
the decreasing conspicuity of  the MRI finding.  The patient 
was offered a stereotactic core biopsy but declined in favor 
of  follow-up mammography.  
The patient, still off  HRT, returned for mammography 
of  the left breast in July of  2002.  This mammogram dem-
onstrated the mass had continued to decrease in size, meas-
uring 3 mm (Figure 4 a-c).  The patient was advised to re-
sume a screening schedule of  mammography and in De-
cember of  2002 the mass had resolved completely (Figure 5 
a-c).  
In January of  2003, the patient began using vaginal 
cream containing Estradiol.  A 10 mm mass was observed 
on screening mammography in December of  2003, and 
confirmed on diagnostic mammography in January of  
2004 in the exact location of  the previously identified find-
ing, in the upper inner left breast (Figure 6 a-c).  Ultra-
sound revealed a corresponding 10 mm hypoechoic mass 
with a thick hyperechoic rim in the left upper inner left 
breast (Figure 7a).    An ultrasound-guided core biopsy 
(Figure 7b) and clip placement (Figure 7c) were performed. 
Post-procedure mammography showed the clip to be lo
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1A 1B 1C
Figure 1.  A 64-year-old asymptomatic female presents for screening and subsequent diagnostic mammography:  1A) Left mediolateral 
oblique (MLO) demonstrates a mass in the upper breast (large arrow) while the smaller arrows denote an artery for anatomic reference, 1B) 
Craniocaudal (CC) view shows that the mass is in the inner left breast (solid arrow)— dust artifact is noted medial to this finding (open arrow), 
1C) spot compression magnification view in the CC projection confirms a mass in the left inner breast (large arrow).
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Figure 2 (A-D). Four sequential frames with 2 mm slice thickness from three dimensional fat suppressed T1-weighted gradient recalled echo 
sequence (from just medial to the nipple proceeding medially) obtained approximately 9 minutes after Gd-DTPA contrast injection demonstrate 
a spiculated mass in the left upper slightly inner breast (arrow).
2A 2B
2C 2D
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3A 3B
3C 3D
Figure 3 (A-D).   Six weeks after the initial breast MRI, a repeat study for the purpose of needle localization was performed.  Four sequential 
frames using the same slice thickness in the same location from a T1-fat-suppressed imaging obtained two minutes after contrast injection 
demonstrate significantly diminished size and enhancement of the mass (arrow). The breast anatomy appears slightly different due to light 
compression placed during the needle localization procedure.
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Figure 4. Six months after the initial mammogram: 4A) left 
MLO (smaller arrows denote an artery for anatomic reference), 
4B) CC, and 4C) photographic magnification in the CC projec-
tion demonstrate that the mass has decreased in size (large 
arrow).
4A
                                       
                                                4C
4B
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5B5A
5C
Figure 5. One year after the initial mammogram: 5A) 
left MLO (smaller arrows denote an artery for anatomic 
reference), 5B) CC, and 5C) photographic magnification 
in the CC projection (arrow denotes the area of interest) 
demonstrate that the mass has disappeared.
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Figure 6. Two years after the initial mammogram, 6A) left MLO 
(smaller arrows denote an artery for anatomic reference), 6B) CC, 
and 6C) photographic magnification in the CC projection demon-
strate that the mass has recurred (large arrow).
cated in the anterior aspect of  the mass (Figure 8 a-c).  Bi-
opsy showed invasive lobular carcinoma.  Needle localiza-
tion and subsequent lumpectomy revealed a 12 mm, grade 
1, invasive lobular carcinoma with ductal features.  
Estrogen/progesterone receptors (ER/PR) were strongly 
positive.  Sentinel lymph node biopsy was negative with 
four lymph nodes removed.  The patient was treated with 
radiation therapy and tamoxifen.  The patient remains dis-
ease free one year after her diagnosis. 
Discussion
Understanding the natural history of  breast cancer is 
critically important in the effective and appropriate diagno-
sis and treatment of  the disease.  The medical community 
has generally operated under the assumption that invasive 
breast cancers typically progress and only rarely regress 
spontaneously.  Several epidemiologic concepts have been 
cited as evidence that small breast cancers may cease grow-
ing or regress spontaneously including: 1) cancer incidence 
is significantly higher in screened versus non-screened 
populations, 2) the cumulative breast cancer incidence is 
higher than what would be expected based on a prevalence 
screening round, and 3) no subsequent decrease in cancer 
incidence is seen with cessation of  mammographic screen-
ing. (5)
One review of  the literature found 32 reported cases of  
spontaneous remission of  breast cancer and the histologic 
diagnosis was only sufficiently documented in six of  these 
cases.(1)  Several malignant neoplasms, other than primary 
breast tumors, have shown the ability to regress spontane-
ously.  These include lymphoma, hepatocellular carcinoma, 
and pediatric neuroblastoma among others.  In general, the 
number of  such cases is extremely small.  The notable ex-
ception is neuroblastoma in infants which frequently re-
gresses or matures spontaneously.(6-8)
The biologic mechanism behind regression of  malignant 
neoplasm is unknown.  In cancers such as hepatocellular 
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Figure 7. Ultrasound images of the left upper inner breast (all 
in the transverse plane) demonstrate: 7A) a 10 cm hypoechoic 
mass with a thick hyperechoic rim (arrow), 7B) ultrasound 
guided biopsy of the mass (arrow), and 7C) the mass (large 
arrow) following placement of a clip (small arrow) just adjacent 
to the mass
7C
7B7A
carcinoma, an immune response to the tumor is cited as the 
causative agent.(9)  An immune influence is also associated 
with transplant-related malignancies.  Post-transplant lym-
phoproliferative disorder is a direct consequence of  chronic 
immunosuppression and resulting infection by Epstein-Barr 
virus.  If  detected early, most cases resolve with reduction of 
immunosuppressive therapy.(10)  In breast cancer, a de-
crease in either intrinsic or extrinsic female hormones may 
be a mechanism for tumor regression. 
While an in depth discussion of  the relationship of  breast 
cancer and hormones is beyond the scope of  this manu-
script, a brief  consideration of  available evidence that es-
trogen may have played a role in this patient’s care is im-
portant. Observational studies have repeatedly shown a 
correlation between estrogen-based hormone replacement 
regimens and the development of  breast cancer.(11, 12) 
The Women’s Health Initiative (WHI) study, the largest 
randomized controlled trial to investigate the effects of  
HRT, was stopped because the correlation between estro-
gen and progesterone therapy and the development of  
breast cancer appeared to outweigh any significant benefit 
of  HRT.(13) Interestingly, the number of  ER/PR positive 
cancers did not differ significantly between the HRT and 
the placebo groups in the WHI study.(14)  Finally, it has 
been well established that selective estrogen receptor modu-
lator drugs like tamoxifen are effective in the treatment of  
breast cancer.(15) In fact, such drugs have been shown to 
play a role in breast cancer prevention.(16)  While the link 
between tumor receptor status and breast cancer develop-
ment, growth, and possible regression is undoubtedly im-
portant, the precise mechanisms remain uncertain.
Most of  the prior case reports suggest but none defini-
tively establish a link between hormone use, and tumor 
evolution.(1, 17)  Most of  the previously reported cases are 
so old that tumor hormone receptor status was unlikely 
evaluated.  Though our case report documents a possible 
association between ER/PR positivity, estrogen/
progesterone therapy discontinuation, and tumor regres-
sion, a cause-and-effect relationship cannot be inferred 
without further study. Recent research has proposed to look 
at tumor biomarkers to determine which breast cancers 
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Figure 8. Following ultrasound guided core biopsy; 8A) left MLO 
(smaller arrows denote an artery for anatomic reference), 8B) CC, 
and 8C) photographic magnification in the CC projection demon-
strate the mass (large solid arrow) and a radioopaque marking clip 
(large open arrow) placed in the anterior lateral aspect of the tumor. 
8B8A
8C
may regress under certain conditions.(2)  Although basing 
therapeutic decisions on specific tumor characteristics ap-
pears promising, such research is in its infancy.  
The unnecessary treatment of  breast neoplasms not des-
tined to impact survival is not a new concept.  The increas-
ing number of  DCIS diagnoses and subsequent therapies, 
which parallel rates of  mammographic screening, have 
raised concerns of  over-treatment.(18)  Similarly, if  a pro-
portion of  invasive breast cancers will ultimately regress, 
over-treatment may be occurring.  Unfortunately, current 
technology does not allow accurate distinction of  which 
cases of  breast cancer will lead to morbidity and mortality 
if  left untreated.  Therefore, we treat virtually all cases.  
Regression of  malignant neoplasms in a screening setting 
is extremely difficult to document with certainty because 
the candidate neoplasms will most likely be very small.  
Two scenarios exist in which tumor regression can be 
documented.  A patient can undergo percutaneous biopsy 
proving malignancy and then refuse treatment.  If  the tu-
mor disappears, this may qualify as tumor regression.  Un-
fortunately, the biopsy itself  may be cited as the causative 
factor of  regression either by completely removing the tu-
mor or disrupting its blood supply.  The second scenario 
demonstrating regression is shown in our case report—a 
suspicious mass regresses before biopsy is performed.  With 
recrudescence of  this tumor, we have indirect evidence that 
it has regressed only to recur subsequent to the reinstitution 
of  estrogen therapy.  In this case, we simply do not have 
histologic proof  of  the initial diagnosis.  Considering the 
difficulty of  definitively proving regression beyond a 
shadow of  a doubt, the case presented here, with its con-
vincing imaging features, is strong evidence of  this phe-
nomenon. The difficulty in documenting breast cancer re-
gression makes directly measuring the frequency of  this 
phenomenon as a percentage of  all invasive breast cancers 
impossible.  Alternative strategies, such as simulation mod-
eling, may provide some answers.  Until reliable predictors 
of  future tumor regression become available, all invasive 
breast cancers must be assumed to be life threatening.
In conclusion, we believe this case is a compelling exam-
ple of  breast cancer that transiently regressed after cessa-
tion of  estrogen and progesterone replacement therapy.  It 
is impossible to surmise how common such an occurrence 
might be without further study.  Future investigation into 
this phenomenon will be critically important not only for 
individual treatment decisions but also in determining the 
optimal deployment of  population based detection and 
treatment resources.
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